BerGenBio ASA: Results for the Second Quarter and Half year 2017
(WorldNews Norway)

Bergen, Norway, 18 August 2017 - BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces its results for the second quarter and half year 2017. A presentation of the results by the Company`s senior management team will take place today at 10.00 am CEST in Oslo - details below. Richard Godfrey, Chief Executive Officer of BerGenBio, commented: `During the first half of 2017, BerGenBio has undergone substantial development and made important progress: the Company has completed a successful IPO; signed a clinical collaboration agreement with Merck & Co (MSD); and initiated a programme of Phase 2...